Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyHydromorphone
Identification
- Name
- Hydromorphone
- Accession Number
- DB00327 (APRD01021)
- Type
- Small Molecule
- Groups
- Approved, Illicit
- Description
An opioid analgesic derived from morphine and used mainly as an analgesic. It has a shorter duration of action and is more potent than morphine. [PubChem]
- Structure
Structure for DB00327 (Hydromorphone)
- Synonyms
- (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one
- 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one
- 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone
- 6-Deoxy-7,8-dihydro-6-oxomorphine
- 7,8-Dihydromorphinone
- Dihydromorfinon
- Dihydromorphinone
- Dimorphone
- Hidromorfona
- Hydromorfona
- Hydromorphone
- Hydromorphonum
- Idromorfone
- External IDs
- IDS-NH-004 / N02AA03 / NSC-19046
- Product Ingredients
Ingredient UNII CAS InChI Key Hydromorphone Hydrochloride L960UP2KRW 71-68-1 XHILEZUETWRSHC-NRGUFEMZSA-N Hydromorphone sulfate 75Y990NH3Z 25333-57-7 JBBINZRUTLUBFR-NRGUFEMZSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Dilaudid Injection, solution 1 mg/mL Intramuscular; Intravenous; Subcutaneous Purdue Pharma LP 1926-01-01 2017-02-01 US 
Dilaudid Tablet 8 mg/1 Oral Rhodes Pharmaceuticals, L.P. 2017-05-15 Not applicable US Dilaudid Liquid 5 mg/5mL Oral Purdue Pharma LP 1956-01-01 Not applicable US Dilaudid Tablet 4 mg/1 Oral Lake Erie Medical Dba Quality Care Produts Llc 1956-01-01 2016-12-21 US Dilaudid Injection, solution 4 mg/mL Intramuscular; Intravenous; Subcutaneous Fresenius Kabi 2016-12-16 2018-02-09 US Dilaudid Liquid 1 mg Oral Purdue Pharma 1989-12-31 Not applicable Canada 
Dilaudid Tablet 4 mg/1 Oral Purdue Pharma LP 1956-01-01 Not applicable US Dilaudid Injection, solution 4 mg/mL Intramuscular; Intravenous; Subcutaneous Purdue Pharma LP 1926-01-01 Not applicable US Dilaudid Tablet 8 mg Oral Purdue Pharma 1989-12-31 Not applicable Canada Dilaudid Tablet 4 mg Oral Purdue Pharma 1984-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-hydromorphone Tablet 4 mg Oral Apotex Corporation 2012-12-18 Not applicable Canada Apo-hydromorphone Tablet 2 mg Oral Apotex Corporation 2012-12-18 Not applicable Canada Apo-hydromorphone Tablet 8 mg Oral Apotex Corporation 2012-12-18 Not applicable Canada Apo-hydromorphone Tablet 1 mg Oral Apotex Corporation 2012-12-18 Not applicable Canada Bar-hydromorphone HCl Capsule, extended release 30 mg Oral Bard Pharmaceuticals (1990) Inc Not applicable Not applicable Canada Bar-hydromorphone HCl Capsule, extended release 12 mg Oral Bard Pharmaceuticals (1990) Inc Not applicable Not applicable Canada Bar-hydromorphone HCl Capsule, extended release 4.5 mg Oral Bard Pharmaceuticals (1990) Inc Not applicable Not applicable Canada Bar-hydromorphone HCl Capsule, extended release 24 mg Oral Bard Pharmaceuticals (1990) Inc Not applicable Not applicable Canada Bar-hydromorphone HCl Capsule, extended release 9 mg Oral Bard Pharmaceuticals (1990) Inc Not applicable Not applicable Canada Bar-hydromorphone HCl Capsule, extended release 3 mg Oral Bard Pharmaceuticals (1990) Inc Not applicable Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Hydromorphone HCl Hydromorphone Hydrochloride (.2 mg/mL) Injection, solution Intravenous Cantrell Drug Company 2010-08-23 2017-12-22 US Hydromorphone HCl Hydromorphone Hydrochloride (.5 mg/mL) Injection, solution Intramuscular; Intravenous; Subcutaneous Cantrell Drug Company 2012-01-18 Not applicable US Hydromorphone HCl Hydromorphone Hydrochloride (10 mg/mL) Injection, solution Intravenous Cantrell Drug Company 2014-08-13 Not applicable US Hydromorphone HCl Hydromorphone Hydrochloride (.1 mg/mL) Injection, solution Intravenous Cantrell Drug Company 2014-08-21 Not applicable US Hydromorphone HCl Hydromorphone Hydrochloride (1 mg/mL) Injection, solution Intravenous Cantrell Drug Company 2011-06-30 2017-12-22 US Hydromorphone HCl Hydromorphone Hydrochloride (.4 mg/mL) Injection, solution Intravenous Cantrell Drug Company 2014-08-13 Not applicable US Hydromorphone HCl Hydromorphone Hydrochloride (2 mg/mL) Injection, solution Intravenous Cantrell Drug Company 2014-08-13 Not applicable US Hydromorphone Hydrochloride Hydromorphone Hydrochloride (2 mg/mL) Injection Intramuscular; Intravenous; Subcutaneous West Ward Pharmaceutical 1972-01-01 Not applicable US Hydromorphone Hydrochloride Hydromorphone Hydrochloride (3 mg/1) Suppository Rectal Paddock Laboratories, Inc. 1996-01-31 Not applicable US Hydromorphone Hydrochloride Hydromorphone Hydrochloride (2 mg/mL) Injection Intramuscular; Intravenous; Subcutaneous West Ward Pharmaceutical 1972-01-01 Not applicable US - International/Other Brands
- Palladone
- Categories
- Alkaloids
- Analgesics
- Central Nervous System Agents
- Central Nervous System Depressants
- Morphinans
- Morphine Derivatives
- Narcotics
- Natural Opium Alkaloids
- Nervous System
- Opiate Agonists
- Opiate Alkaloids
- Opioid Agonist
- Opioids
- Peripheral Nervous System Agents
- Phenanthrenes
- Semi-synthetic Opioids
- Sensory System Agents
- UNII
- Q812464R06
- CAS number
- 466-99-9
- Weight
- Average: 285.3377
Monoisotopic: 285.136493479 - Chemical Formula
- C17H19NO3
- InChI Key
- WVLOADHCBXTIJK-YNHQPCIGSA-N
- InChI
- InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
- IUPAC Name
- (1S,5R,13R,17R)-10-hydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
- SMILES
- [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Pharmacology
- Indication
For the relief of moderate to severe pain such as that due to surgery, cancer, trauma/injury, or burns.
- Associated Conditions
- Pharmacodynamics
Hydromorphone is a hydrogenated ketone derivative of morphine that acts as a narcotic analgesic. It has a shorter duration of action than morphine. Hydromorphone is approximately 8 times more potent on a milligram basis than morphine. In addition, hydromorphone is better absorbed orally than is morphine. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Hydromorphone appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.
- Mechanism of action
Hydromorphone is a narcotic analgesic; its principal therapeutic effect is relief of pain. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Hydromorphone also binds with kappa-receptors which are thought to mediate spinal analgesia, miosis and sedation.
Target Actions Organism AMu-type opioid receptor agonistHuman ADelta-type opioid receptor partial agonistHuman AKappa-type opioid receptor agonistHuman - Absorption
Better absorbed orally than morphine
- Volume of distribution
- Not Available
- Protein binding
20%
- Metabolism
Primarily hepatic. After absorption hydromorphone is metabolized by the liver to the glucuronide conjugate which is then excreted in the urine. Hydromorphone is metabolized to the major metabolites hydromorphone-3-glucuronide, hydromorphone-3-glucoside and dihydroisomorphine-6-glucuronide.
- Hydromorphone Dihydromorphine
- Hydromorphone Dihydroisomorphine
- Hydromorphone Norhydromorphone
- Hydromorphone Hydromorphone 3-beta-O-glucuronide
- Hydromorphone Dihydroisomorphine-6-glucuronide
- Hydromorphone Hydromorphone-3-glucoside
- Hydromorphone Hydromorphone-3-glucuronide
- Hydromorphone Hydromorphone-3-sulphate
- Route of elimination
Only a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.
- Half life
2.6 hours (oral); 18.6 hours for sustained release Palladone
- Clearance
- 1.96 L/min
- Toxicity
Hydromorphone is a schedule II narcotic which can lead to physical dependence or addiction. High doses lead to respiratory depression, nausea, and vomiting. Overdoses lead to extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Hydromorphone Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Hydromorphone. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Hydromorphone. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydromorphone. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydromorphone. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Hydromorphone is combined with 7-Nitroindazole. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when Hydromorphone is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Experimental Abiraterone The serum concentration of Hydromorphone can be increased when it is combined with Abiraterone. Approved Acepromazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Aceprometazine. Approved Acetazolamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Acetazolamide. Approved, Vet Approved Acetyl sulfisoxazole The metabolism of Hydromorphone can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Hydromorphone. Approved Adipiplon The risk or severity of adverse effects can be increased when Hydromorphone is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Agomelatine. Approved, Investigational Alaproclate Hydromorphone may increase the serotonergic activities of Alaproclate. Experimental Alcuronium The risk or severity of adverse effects can be increased when Alcuronium is combined with Hydromorphone. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfentanil. Approved, Illicit Alimemazine Alimemazine may increase the hypotensive activities of Hydromorphone. Approved, Vet Approved Allopregnanolone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alprazolam. Approved, Illicit, Investigational Alvimopan The risk or severity of adverse effects can be increased when Hydromorphone is combined with Alvimopan. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amiloride. Approved Amiodarone The metabolism of Hydromorphone can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amitriptyline. Approved Ammonium chloride Ammonium chloride may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy. Approved, Investigational, Vet Approved Amobarbital The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amperozide. Experimental Amphetamine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Amphetamine. Approved, Illicit, Investigational Anisotropine Methylbromide The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hydromorphone. Approved Apalutamide The serum concentration of Hydromorphone can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Hydromorphone can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Hydromorphone is combined with Aripiprazole. Approved, Investigational Artemether The metabolism of Hydromorphone can be decreased when combined with Artemether. Approved Articaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Asenapine. Approved Atazanavir The metabolism of Hydromorphone can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Hydromorphone can be decreased when combined with Atomoxetine. Approved Atracurium The risk or severity of adverse effects can be increased when Atracurium is combined with Hydromorphone. Approved, Experimental, Investigational Atracurium besylate The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydromorphone. Approved Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Hydromorphone. Approved, Vet Approved Azaperone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Azaperone. Investigational, Vet Approved Azelastine Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azosemide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Azosemide. Investigational Baclofen The risk or severity of adverse effects can be increased when Hydromorphone is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital. Illicit Benactyzine The risk or severity of adverse effects can be increased when Benactyzine is combined with Hydromorphone. Withdrawn Bendroflumethiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bendroflumethiazide. Approved Benmoxin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benmoxin. Withdrawn Benperidol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benperidol. Approved, Investigational Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Hydromorphone. Approved Benzocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzocaine. Approved, Investigational Benzphetamine Benzphetamine may increase the analgesic activities of Hydromorphone. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzyl alcohol. Approved Betaxolol The metabolism of Hydromorphone can be decreased when combined with Betaxolol. Approved, Investigational Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Hydromorphone. Approved, Investigational BL-1020 BL-1020 may increase the hypotensive activities of Hydromorphone. Investigational Boceprevir The metabolism of Hydromorphone can be decreased when combined with Boceprevir. Approved, Withdrawn Bornaprine The risk or severity of adverse effects can be increased when Bornaprine is combined with Hydromorphone. Experimental Bortezomib The metabolism of Hydromorphone can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Hydromorphone can be decreased when it is combined with Bosentan. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved Brofaromine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brofaromine. Experimental Bromazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromisoval. Experimental Bromotheophylline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromotheophylline. Approved Bromperidol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Brotizolam. Approved, Investigational, Withdrawn Bumetanide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bupivacaine. Approved, Investigational Buprenorphine Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Hydromorphone can be decreased when combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Buspirone. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Hydromorphone. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Hydromorphone is combined with Butethal. Approved, Illicit Butorphanol Butorphanol may decrease the analgesic activities of Hydromorphone. Approved, Illicit, Vet Approved Butylscopolamine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Hydromorphone. Approved, Investigational, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Hydromorphone is combined with Canertinib. Investigational Canrenoic acid The risk or severity of adverse effects can be increased when Hydromorphone is combined with Canrenoic acid. Approved, Withdrawn Canrenone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Canrenone. Investigational Capecitabine The metabolism of Hydromorphone can be decreased when combined with Capecitabine. Approved, Investigational Carbamazepine The metabolism of Hydromorphone can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Hydromorphone is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Carisoprodol. Approved Caroxazone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Caroxazone. Withdrawn Celecoxib The metabolism of Hydromorphone can be decreased when combined with Celecoxib. Approved, Investigational Ceritinib The serum concentration of Hydromorphone can be increased when it is combined with Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlordiazepoxide. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloroprocaine. Approved Chloroquine The metabolism of Hydromorphone can be decreased when combined with Chloroquine. Approved, Investigational, Vet Approved Chlorothiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide. Approved, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorphenamine. Approved Chlorphenoxamine The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydromorphone. Withdrawn Chlorphentermine Chlorphentermine may increase the analgesic activities of Hydromorphone. Illicit, Withdrawn Chlorproethazine Chlorproethazine may increase the hypotensive activities of Hydromorphone. Experimental Chlorpromazine The metabolism of Hydromorphone can be decreased when combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorthalidone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorthalidone. Approved Chlorzoxazone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorzoxazone. Approved Cholecalciferol The metabolism of Hydromorphone can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cicletanine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cicletanine. Investigational Cimetidine The metabolism of Hydromorphone can be decreased when combined with Cimetidine. Approved, Investigational Cinacalcet The metabolism of Hydromorphone can be decreased when combined with Cinacalcet. Approved Cinchocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cinchocaine. Approved, Vet Approved Citalopram The metabolism of Hydromorphone can be decreased when combined with Citalopram. Approved Clarithromycin The metabolism of Hydromorphone can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Hydromorphone can be decreased when combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clidinium. Approved Clobazam The metabolism of Hydromorphone can be decreased when combined with Clobazam. Approved, Illicit Clofenamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clofenamide. Experimental clomethiazole The risk or severity of adverse effects can be increased when Hydromorphone is combined with clomethiazole. Investigational Clomipramine The metabolism of Hydromorphone can be decreased when combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonidine. Approved Clopamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clopamide. Experimental Clopenthixol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorazepate. Approved, Illicit Clorexolone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorexolone. Experimental Clothiapine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Clothiapine. Experimental Clotrimazole The metabolism of Hydromorphone can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Hydromorphone can be decreased when combined with Clozapine. Approved Cobicistat The serum concentration of Hydromorphone can be increased when it is combined with Cobicistat. Approved Cocaine The metabolism of Hydromorphone can be decreased when combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Hydromorphone. Approved, Illicit Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Hydromorphone. Approved, Investigational Crisaborole The metabolism of Hydromorphone can be decreased when combined with Crisaborole. Approved, Investigational Crizotinib The metabolism of Hydromorphone can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Hydromorphone can be decreased when combined with Curcumin. Approved, Investigational Cyclizine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine. Approved Cyclopenthiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclopenthiazide. Experimental Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydromorphone. Approved Cyclopropane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Hydromorphone can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyclothiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclothiazide. Approved Cyproheptadine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyproheptadine. Approved Dabrafenib The serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dapiprazole. Approved Dapoxetine Hydromorphone may increase the serotonergic activities of Dapoxetine. Investigational Darifenacin The metabolism of Hydromorphone can be decreased when combined with Darifenacin. Approved, Investigational Darunavir The serum concentration of Hydromorphone can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Hydromorphone can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Hydromorphone can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Hydromorphone can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desflurane. Approved Desipramine The metabolism of Hydromorphone can be decreased when combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Hydromorphone. Approved, Investigational Desmopressin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin. Approved Desvenlafaxine Hydromorphone may increase the serotonergic activities of Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine. Approved Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Hydromorphone. Withdrawn Dexmedetomidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexmedetomidine. Approved, Vet Approved Dextroamphetamine Dextroamphetamine may increase the analgesic activities of Hydromorphone. Approved, Illicit Dextromoramide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diazepam. Approved, Illicit, Investigational, Vet Approved Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone. Approved Diethyl ether The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diethyl ether. Experimental Diethylpropion Diethylpropion may increase the analgesic activities of Hydromorphone. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydrocodeine. Approved, Illicit Dihydroergotamine The metabolism of Hydromorphone can be decreased when combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Hydromorphone can be decreased when combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dimenhydrinate. Approved Diphenhydramine The metabolism of Hydromorphone can be decreased when combined with Diphenhydramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenoxylate. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Doramectin. Vet Approved Dosulepin The metabolism of Hydromorphone can be decreased when combined with Dosulepin. Approved Doxepin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Doxepin. Approved, Investigational Doxycycline The metabolism of Hydromorphone can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Hydromorphone is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved, Illicit Dronedarone The metabolism of Hydromorphone can be decreased when combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved, Vet Approved Drospirenone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Drospirenone. Approved Drotebanol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Drotebanol. Experimental, Illicit Duloxetine The metabolism of Hydromorphone can be decreased when combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecopipam. Investigational Efavirenz The metabolism of Hydromorphone can be decreased when combined with Efavirenz. Approved, Investigational Efonidipine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Efonidipine. Approved, Investigational Eliglustat The metabolism of Hydromorphone can be decreased when combined with Eliglustat. Approved Eltanolone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eltanolone. Investigational Eluxadoline Hydromorphone may increase the constipating activities of Eluxadoline. Approved, Investigational Emepronium The risk or severity of adverse effects can be increased when Emepronium is combined with Hydromorphone. Experimental Enflurane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Entacapone. Approved, Investigational Enzalutamide The serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide. Approved Epitizide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Epitizide. Experimental Eplerenone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eplerenone. Approved Erythromycin The metabolism of Hydromorphone can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram Hydromorphone may increase the serotonergic activities of Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Eszopiclone. Approved, Investigational Etacrynic acid The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etacrynic acid. Approved, Investigational Etanautine The risk or severity of adverse effects can be increased when Etanautine is combined with Hydromorphone. Experimental Ethanol Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethopropazine The risk or severity of adverse effects can be increased when Ethopropazine is combined with Hydromorphone. Approved Ethosuximide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethotoin. Approved Ethoxzolamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethoxzolamide. Withdrawn Ethyl carbamate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etomidate. Approved Etoperidone Hydromorphone may increase the serotonergic activities of Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etorphine. Illicit, Vet Approved Etravirine The metabolism of Hydromorphone can be decreased when combined with Etravirine. Approved Etybenzatropine The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Hydromorphone. Experimental Ezogabine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fencamfamine. Approved, Illicit, Withdrawn Fenquizone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fenquizone. Experimental Fentanyl The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fesoterodine The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone. Approved Fexofenadine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fexofenadine. Approved, Investigational Flavoxate The risk or severity of adverse effects can be increased when Flavoxate is combined with Hydromorphone. Approved Flibanserin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flibanserin. Approved, Investigational Floxuridine The metabolism of Hydromorphone can be decreased when combined with Floxuridine. Approved Fluanisone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluanisone. Experimental Fluconazole The metabolism of Hydromorphone can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunitrazepam. Approved, Illicit Fluorouracil The metabolism of Hydromorphone can be decreased when combined with Fluorouracil. Approved Fluoxetine The metabolism of Hydromorphone can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluphenazine. Approved Flurazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flurazepam. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluticasone propionate. Approved Fluvastatin The metabolism of Hydromorphone can be decreased when combined with Fluvastatin. Approved Fluvoxamine The metabolism of Hydromorphone can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Hydromorphone can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Hydromorphone can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The metabolism of Hydromorphone can be increased when combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fospropofol. Approved, Illicit, Investigational Furazolidone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Furazolidone. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Hydromorphone can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin Enacarbil. Approved, Investigational Gallamine The risk or severity of adverse effects can be increased when Gallamine is combined with Hydromorphone. Experimental Gallamine Triethiodide The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Hydromorphone. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gemfibrozil The metabolism of Hydromorphone can be decreased when combined with Gemfibrozil. Approved Gepefrine Gepefrine may increase the analgesic activities of Hydromorphone. Experimental Gepirone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Glutethimide. Approved, Illicit Glycopyrronium The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydromorphone. Approved, Investigational, Vet Approved Guanfacine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The metabolism of Hydromorphone can be decreased when combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane. Approved, Vet Approved Harmaline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Harmaline. Experimental Heroin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hexobarbital. Approved Homatropine The risk or severity of adverse effects can be increased when Homatropine is combined with Hydromorphone. Approved Hydracarbazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydracarbazine. Experimental Hydrochlorothiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydrochlorothiazide. Approved, Vet Approved Hydrocodone Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydroflumethiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydroflumethiazide. Approved, Investigational Hydroxyamphetamine Hydroxyamphetamine may increase the analgesic activities of Hydromorphone. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydromorphone. Approved Ibopamine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ibopamine. Experimental Idelalisib The metabolism of Hydromorphone can be decreased when combined with Idelalisib. Approved Iloperidone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iloperidone. Approved Imatinib The metabolism of Hydromorphone can be decreased when combined with Imatinib. Approved Imipramine The metabolism of Hydromorphone can be decreased when combined with Imipramine. Approved Indalpine Hydromorphone may increase the serotonergic activities of Indalpine. Investigational, Withdrawn Indapamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Indapamide. Approved Indinavir The metabolism of Hydromorphone can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Hydromorphone is combined with Indiplon. Investigational Iofetamine I-123 Iofetamine I-123 may increase the analgesic activities of Hydromorphone. Approved Ipratropium The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydromorphone. Approved Iproclozide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iproclozide. Withdrawn Iproniazid The risk or severity of adverse effects can be increased when Hydromorphone is combined with Iproniazid. Withdrawn Irbesartan The metabolism of Hydromorphone can be decreased when combined with Irbesartan. Approved, Investigational Isavuconazole The serum concentration of Hydromorphone can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Hydromorphone can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid The risk or severity of adverse effects can be increased when Hydromorphone is combined with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Isoflurane. Approved, Vet Approved Isoniazid The metabolism of Hydromorphone can be decreased when combined with Isoniazid. Approved, Investigational Isosorbide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Isosorbide. Approved, Investigational Isradipine The metabolism of Hydromorphone can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Hydromorphone can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Hydromorphone can be increased when it is combined with Ivacaftor. Approved Ketamine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Hydromorphone can be decreased when combined with Ketoconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lamotrigine. Approved, Investigational Leflunomide The metabolism of Hydromorphone can be decreased when combined with Leflunomide. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran Hydromorphone may increase the serotonergic activities of Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Levorphanol. Approved Lidocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lidocaine. Approved, Vet Approved Lisdexamfetamine Lisdexamfetamine may increase the analgesic activities of Hydromorphone. Approved, Investigational Lithium cation The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lithium. Experimental Lobeglitazone The metabolism of Hydromorphone can be decreased when combined with Lobeglitazone. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Hydromorphone can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir The metabolism of Hydromorphone can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Hydromorphone. Approved Lorcaserin The metabolism of Hydromorphone can be decreased when combined with Lorcaserin. Approved Lormetazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Hydromorphone can be increased when it is combined with Lorpiprazole. Approved Losartan The metabolism of Hydromorphone can be decreased when combined with Losartan. Approved Lovastatin The metabolism of Hydromorphone can be decreased when combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loxapine. Approved Luliconazole The serum concentration of Hydromorphone can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Hydromorphone can be decreased when it is combined with Lumacaftor. Approved Lumefantrine The metabolism of Hydromorphone can be decreased when combined with Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Hydromorphone can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The metabolism of Hydromorphone can be decreased when combined with Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mannitol. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline. Approved, Investigational Mazaticol The risk or severity of adverse effects can be increased when Mazaticol is combined with Hydromorphone. Experimental Mebanazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mebanazine. Withdrawn Mebicar The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mebicar. Experimental Mebutizide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mebutizide. Experimental Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone. Approved, Investigational Meclizine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Medetomidine. Vet Approved Mefruside The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mefruside. Experimental Melatonin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Melperone. Approved, Investigational Mephedrone Mephedrone may increase the analgesic activities of Hydromorphone. Investigational Mephentermine Mephentermine may increase the analgesic activities of Hydromorphone. Approved Mepivacaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meptazinol. Experimental Mersalyl The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mersalyl. Approved Mesoridazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Metaxalone. Approved Methadone The metabolism of Hydromorphone can be decreased when combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methadyl Acetate. Approved, Illicit Methamphetamine Methamphetamine may increase the analgesic activities of Hydromorphone. Approved, Illicit Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Hydromorphone. Approved, Investigational Methapyrilene The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methaqualone. Illicit, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methazolamide. Approved Methocarbamol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methohexital. Approved Methotrimeprazine Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Methoxyphenamine may increase the analgesic activities of Hydromorphone. Experimental Methscopolamine The risk or severity of adverse effects can be increased when Methscopolamine is combined with Hydromorphone. Approved Methsuximide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyclothiazide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylecgonine. Experimental Methylene blue The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylene blue. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylphenobarbital. Approved Methylscopolamine bromide The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Hydromorphone. Approved Meticrane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meticrane. Experimental Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Hydromorphone. Approved Metolazone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone. Approved Metoprolol The metabolism of Hydromorphone can be decreased when combined with Metoprolol. Approved, Investigational Metyrosine Hydromorphone may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam. Approved, Illicit Midomafetamine Midomafetamine may increase the analgesic activities of Hydromorphone. Experimental, Illicit, Investigational Midostaurin The metabolism of Hydromorphone can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Hydromorphone can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran Hydromorphone may increase the serotonergic activities of Milnacipran. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Minaprine. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved, Investigational Mirabegron The metabolism of Hydromorphone can be decreased when combined with Mirabegron. Approved Mirtazapine Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitotane The serum concentration of Hydromorphone can be decreased when it is combined with Mitotane. Approved MMDA MMDA may increase the analgesic activities of Hydromorphone. Experimental, Illicit Moclobemide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Moclobemide. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Molindone. Approved Moricizine Moricizine may increase the hypotensive activities of Hydromorphone. Approved, Investigational, Withdrawn Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone. Approved, Investigational Muzolimine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Muzolimine. Experimental Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved, Investigational Nalbuphine Nalbuphine may decrease the analgesic activities of Hydromorphone. Approved Naltrexone The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Naltrexone. Approved, Investigational, Vet Approved Nefazodone The metabolism of Hydromorphone can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Hydromorphone can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Hydromorphone can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Hydromorphone can be increased when combined with Nevirapine. Approved Nialamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nialamide. Withdrawn Nicardipine The metabolism of Hydromorphone can be decreased when combined with Nicardipine. Approved, Investigational Nilotinib The metabolism of Hydromorphone can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrous oxide. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Nortriptyline. Approved Octamoxin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Octamoxin. Withdrawn Olanzapine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Olanzapine. Approved, Investigational Olaparib The metabolism of Hydromorphone can be decreased when combined with Olaparib. Approved Olopatadine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Olopatadine. Approved Omeprazole The metabolism of Hydromorphone can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Ondansetron The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Hydromorphone is combined with Opium. Approved, Illicit Orphenadrine Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Hydromorphone is combined with Osanetant. Investigational Osimertinib The serum concentration of Hydromorphone can be increased when it is combined with Osimertinib. Approved Otilonium The risk or severity of adverse effects can be increased when Otilonium is combined with Hydromorphone. Experimental, Investigational Oxazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxazepam. Approved Oxitropium The risk or severity of adverse effects can be increased when Oxitropium is combined with Hydromorphone. Investigational Oxprenolol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxybuprocaine. Approved, Investigational Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxymorphone. Approved, Investigational, Vet Approved Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydromorphone. Approved Palbociclib The serum concentration of Hydromorphone can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone. Approved Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Hydromorphone. Approved Panobinostat The serum concentration of Hydromorphone can be increased when it is combined with Panobinostat. Approved, Investigational Paraldehyde Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Pargyline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pargyline. Approved Paroxetine The metabolism of Hydromorphone can be decreased when combined with Paroxetine. Approved, Investigational Peginterferon alfa-2b The serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b. Approved Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone. Approved Penfluridol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Penfluridol. Experimental Pentazocine Pentazocine may decrease the analgesic activities of Hydromorphone. Approved, Vet Approved Pentobarbital The metabolism of Hydromorphone can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Hydromorphone. Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved Perazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Perphenazine. Approved Pethidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pethidine. Approved Phenazocine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenazocine. Experimental Phenelzine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenelzine. Approved Phenglutarimide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Hydromorphone. Experimental Phenibut The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenibut. Experimental Pheniprazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pheniprazine. Withdrawn Phenobarbital The metabolism of Hydromorphone can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoxyethanol. Approved Phenoxypropazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoxypropazine. Withdrawn Phentermine Phentermine may increase the analgesic activities of Hydromorphone. Approved, Illicit Phenytoin The metabolism of Hydromorphone can be increased when combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pimozide. Approved Pipamperone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipamperone. Approved, Investigational Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydromorphone. Approved Pipotiazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipotiazine. Approved, Investigational Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone. Approved Piretanide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Piretanide. Approved Piritramide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Piritramide. Approved, Investigational Pirlindole The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pirlindole. Approved Pitolisant The serum concentration of Hydromorphone can be decreased when it is combined with Pitolisant. Approved, Investigational Pivhydrazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pivhydrazine. Withdrawn Pizotifen The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pizotifen. Approved Polythiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Polythiazide. Approved Pomalidomide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide. Approved Posaconazole The metabolism of Hydromorphone can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Potassium cation The risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium. Approved, Investigational Potassium Citrate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium Citrate. Approved, Investigational, Vet Approved Pramipexole Hydromorphone may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Hydromorphone can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prilocaine. Approved Primidone The metabolism of Hydromorphone can be increased when combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Procaine. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Procarbazine. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prochlorperazine. Approved, Vet Approved Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Hydromorphone. Approved Promazine The metabolism of Hydromorphone can be decreased when combined with Promazine. Approved, Vet Approved Promethazine Promethazine may increase the hypotensive activities of Hydromorphone. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Hydromorphone is combined with Propanidid. Experimental Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Hydromorphone. Approved Proparacaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Proparacaine. Approved, Vet Approved Propericiazine Propericiazine may increase the hypotensive activities of Hydromorphone. Approved, Investigational Propiopromazine Propiopromazine may increase the hypotensive activities of Hydromorphone. Vet Approved Propiverine The risk or severity of adverse effects can be increased when Propiverine is combined with Hydromorphone. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Propofol. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Hydromorphone is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Hydromorphone is combined with PSD502. Investigational Pseudoephedrine Pseudoephedrine may increase the analgesic activities of Hydromorphone. Approved Pyrimethamine The metabolism of Hydromorphone can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quetiapine. Approved Quinethazone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinethazone. Approved Quinidine The metabolism of Hydromorphone can be decreased when combined with Quinidine. Approved, Investigational Quinine The metabolism of Hydromorphone can be decreased when combined with Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ramelteon. Approved, Investigational Ramosetron Hydromorphone may increase the constipating activities of Ramosetron. Approved, Investigational Ranolazine The metabolism of Hydromorphone can be decreased when combined with Ranolazine. Approved, Investigational Rasagiline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Rasagiline. Approved Remifentanil The risk or severity of adverse effects can be increased when Hydromorphone is combined with Remifentanil. Approved Remoxipride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Hydromorphone. Approved, Investigational Rifabutin The metabolism of Hydromorphone can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Hydromorphone can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Hydromorphone can be increased when combined with Rifapentine. Approved, Investigational Rilpivirine The serum concentration of Hydromorphone can be decreased when it is combined with Rilpivirine. Approved Risperidone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ritanserin. Investigational Ritobegron Ritobegron may increase the analgesic activities of Hydromorphone. Investigational Ritonavir The metabolism of Hydromorphone can be decreased when combined with Ritonavir. Approved, Investigational Rolapitant The metabolism of Hydromorphone can be decreased when combined with Rolapitant. Approved, Investigational Rolofylline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Rolofylline. Investigational Romifidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Romifidine. Vet Approved Ropinirole Hydromorphone may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ropivacaine. Approved Rotigotine Hydromorphone may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Hydromorphone can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Hydromorphone. Approved Safrazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Safrazine. Withdrawn Saquinavir The metabolism of Hydromorphone can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Sarilumab. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone. Approved, Investigational Secobarbital The metabolism of Hydromorphone can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Selegiline. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The metabolism of Hydromorphone can be decreased when combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sevoflurane. Approved, Vet Approved Sildenafil The metabolism of Hydromorphone can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Hydromorphone can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Hydromorphone can be increased when it is combined with Simeprevir. Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved Solifenacin The risk or severity of adverse effects can be increased when Solifenacin is combined with Hydromorphone. Approved Sorafenib The metabolism of Hydromorphone can be decreased when combined with Sorafenib. Approved, Investigational Spiradoline The risk or severity of adverse effects can be increased when Hydromorphone is combined with Spiradoline. Investigational Spironolactone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Spironolactone. Approved St. John's Wort The serum concentration of Hydromorphone can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Hydromorphone can be increased when it is combined with Stiripentol. Approved Succinylcholine Succinylcholine may increase the bradycardic activities of Hydromorphone. Approved Sufentanil The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil. Approved, Investigational Sulfadiazine The metabolism of Hydromorphone can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Hydromorphone can be decreased when combined with Sulfamethoxazole. Approved Sulfisoxazole The metabolism of Hydromorphone can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sultopride. Experimental Suvorexant Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone. Approved Tasimelteon The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tasimelteon. Approved, Investigational Telaprevir The metabolism of Hydromorphone can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Hydromorphone can be decreased when combined with Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Hydromorphone. Approved, Investigational Terbinafine The metabolism of Hydromorphone can be decreased when combined with Terbinafine. Approved, Investigational, Vet Approved Tetrabenazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrodotoxin. Investigational Thalidomide Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theobromine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Theobromine. Approved, Investigational Thiamylal The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiamylal. Approved, Vet Approved Thiazinam Thiazinam may increase the hypotensive activities of Hydromorphone. Experimental Thiethylperazine Thiethylperazine may increase the hypotensive activities of Hydromorphone. Withdrawn Thiopental The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiopental. Approved, Vet Approved Thioproperazine Thioproperazine may increase the hypotensive activities of Hydromorphone. Approved Thioridazine The metabolism of Hydromorphone can be decreased when combined with Thioridazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiapride. Approved, Investigational Ticagrelor The metabolism of Hydromorphone can be decreased when combined with Ticagrelor. Approved Ticlopidine The metabolism of Hydromorphone can be decreased when combined with Ticlopidine. Approved Ticrynafen The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ticrynafen. Withdrawn Tiletamine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tilidine. Experimental Tiotropium The risk or severity of adverse effects can be increased when Tiotropium is combined with Hydromorphone. Approved Tipranavir The metabolism of Hydromorphone can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Hydromorphone can be decreased when it is combined with Tocilizumab. Approved Tolbutamide The metabolism of Hydromorphone can be decreased when combined with Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolcapone. Approved, Withdrawn Toloxatone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Toloxatone. Approved Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Hydromorphone. Approved, Investigational Tolvaptan The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolvaptan. Approved Topiramate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Topiramate. Approved Topiroxostat The metabolism of Hydromorphone can be decreased when combined with Topiroxostat. Approved, Investigational Torasemide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Hydromorphone. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trazodone. Approved, Investigational Triamterene The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene. Approved Triazolam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triazolam. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tricaine methanesulfonate. Vet Approved Trichlormethiazide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichlormethiazide. Approved, Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluoperazine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triflupromazine. Approved, Vet Approved Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydromorphone. Approved Trimethaphan The risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydromorphone. Approved, Investigational Trimethoprim The metabolism of Hydromorphone can be decreased when combined with Trimethoprim. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Triprolidine. Approved Tropatepine The risk or severity of adverse effects can be increased when Tropatepine is combined with Hydromorphone. Experimental Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Hydromorphone. Approved, Investigational Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Hydromorphone. Approved Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydromorphone. Approved Ularitide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ularitide. Investigational Umeclidinium The risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydromorphone. Approved Valproic Acid The risk or severity of adverse effects can be increased when Hydromorphone is combined with Valproic Acid. Approved, Investigational Valsartan The metabolism of Hydromorphone can be decreased when combined with Valsartan. Approved, Investigational Vecuronium The risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone. Approved Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hydromorphone. Approved Venlafaxine The metabolism of Hydromorphone can be decreased when combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Hydromorphone is combined with Veralipride. Experimental Verapamil The metabolism of Hydromorphone can be decreased when combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vigabatrin. Approved Vinyl ether The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vinyl ether. Experimental Voriconazole The metabolism of Hydromorphone can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Hydromorphone is combined with Xenon. Experimental Xipamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Xipamide. Experimental Xylazine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Xylazine. Vet Approved Zafirlukast The metabolism of Hydromorphone can be decreased when combined with Zafirlukast. Approved, Investigational Zaleplon The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zaleplon. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziconotide. Approved Zimelidine Hydromorphone may increase the serotonergic activities of Zimelidine. Withdrawn Ziprasidone The metabolism of Hydromorphone can be decreased when combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zolazepam. Vet Approved Zolpidem Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Take without regard to meals. Avoid alcohol.
References
- Synthesis Reference
Anne M. Hailes, Christopher E. French, Neil C. Bruce, "Morphinone reductase for the preparation of hydromorphone and hydrocodone." U.S. Patent US5571685, issued November, 1990.
US5571685- General References
- Coda BA, Rudy AC, Archer SM, Wermeling DP: Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2003 Jul;97(1):117-23, table of contents. [PubMed:12818953]
- Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL: Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981 Apr;21(4):152-6. [PubMed:6165742]
- External Links
- Human Metabolome Database
- HMDB0014472
- KEGG Compound
- C07042
- PubChem Compound
- 5284570
- PubChem Substance
- 46508700
- ChemSpider
- 4447624
- BindingDB
- 50241341
- ChEBI
- 5790
- ChEMBL
- CHEMBL398707
- Therapeutic Targets Database
- DAP000472
- PharmGKB
- PA449918
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Hydromorphone
- ATC Codes
- N02AA03 — HydromorphoneN02AG04 — Hydromorphone and antispasmodics
- AHFS Codes
- 28:08.08 — Opiate Agonists
- FDA label
- Download (78.9 KB)
- MSDS
- Download (48.3 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Purdue pharma lp
- Purdue pharmaceutical products lp
- Akorn inc
- Barr laboratories inc
- Hospira inc
- Watson laboratories inc
- Roxane laboratories inc
- Mallinckrodt inc
- Actavis totowa llc
- Kv pharmaceutical co
- Lannett holdings inc
- Tyco healthcare mallinckrodt
- Packagers
- Abbott Laboratories Ltd.
- Akorn Inc.
- Barr Pharmaceuticals
- BASF Corp.
- Baxter International Inc.
- Blenheim Pharmacal
- Bristol-Myers Squibb Co.
- Cardinal Health
- D.M. Graham Laboratories Inc.
- Direct Dispensing Inc.
- Endo Pharmaceuticals Inc.
- Ethex Corp.
- Hospira Inc.
- KV Pharmaceutical Co.
- Lake Erie Medical and Surgical Supply
- Lannett Co. Inc.
- Mallinckrodt Inc.
- Mckesson Corp.
- Nucare Pharmaceuticals Inc.
- Paddock Labs
- PD-Rx Pharmaceuticals Inc.
- Pharmakon
- Pharmedium
- Physicians Total Care Inc.
- Purdue Pharma LP
- Qualitest
- Rhodes Pharmaceutical LP
- Roxane Labs
- Stat Rx Usa
- Dosage forms
Form Route Strength Capsule, extended release Oral 9 mg Injection, solution Intramuscular; Intravenous; Subcutaneous 1 mg/mL Injection, solution Intramuscular; Intravenous; Subcutaneous 2 mg/mL Injection, solution Intramuscular; Intravenous; Subcutaneous 4 mg/mL Liquid Intramuscular; Intravenous; Subcutaneous 2 mg Liquid Oral 1 mg Liquid Oral 5 mg/5mL Powder, for solution Intramuscular; Intravenous; Subcutaneous 250 mg Tablet Oral 2 mg/1 Tablet Oral 4 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous; Subcutaneous 10 mg/mL Injection, solution Intramuscular; Intravenous; Subcutaneous 10 mg/mL Liquid Intramuscular; Intravenous; Subcutaneous 10 mg Liquid Intramuscular; Intravenous; Subcutaneous 50 mg Tablet, extended release Oral 12 mg/1 Tablet, extended release Oral 16 mg/1 Tablet, extended release Oral 8 mg/1 Capsule, extended release Oral 4.5 mg Capsule, extended release Oral 12 mg Capsule, extended release Oral 18 mg Capsule, extended release Oral 24 mg Capsule, extended release Oral 30 mg Capsule, extended release Oral 3 mg Capsule, extended release Oral 6 mg Injection, solution Intramuscular; Intravenous; Subcutaneous .5 mg/mL Injection, solution Intravenous .1 mg/mL Injection, solution Intravenous .2 mg/mL Injection, solution Intravenous .4 mg/mL Injection, solution Intravenous 1 mg/mL Injection, solution Intravenous 10 mg/mL Injection, solution Intravenous 2 mg/mL Solution Intramuscular; Intravenous; Subcutaneous 10 mg Solution Intramuscular; Intravenous; Subcutaneous 20 mg Solution Intramuscular; Intravenous; Subcutaneous 50 mg Solution Intramuscular; Intravenous; Subcutaneous 1000 mg Injection Intramuscular; Intravenous; Subcutaneous 2 mg/mL Injection Parenteral 10 mg/mL Solution Oral 1 mg/mL Solution Oral 5 mg/5mL Suppository Rectal 3 mg/1 Tablet Oral 8 mg/1 Tablet, extended release Oral 32 mg/1 Tablet, film coated Oral 2 mg/1 Tablet, film coated Oral 4 mg/1 Tablet, film coated Oral 8 mg/1 Tablet, film coated, extended release Oral 12 mg/1 Tablet, film coated, extended release Oral 16 mg/1 Tablet, film coated, extended release Oral 8 mg/1 Solution Intramuscular; Intravenous; Subcutaneous 100 mg Solution Intramuscular; Intravenous; Subcutaneous 2 mg Tablet, extended release Oral 16 mg Tablet, extended release Oral 32 mg Tablet, extended release Oral 4 mg Tablet, extended release Oral 8 mg Capsule, extended release Oral 16 mg Syrup Oral 1 mg Suppository Rectal 3 mg Tablet Oral 1 mg Tablet Oral 2 mg Tablet Oral 4 mg Tablet Oral 8 mg - Prices
Unit description Cost Unit Hydromorphone hcl powder 166.25USD g Dilaudid-hp 250 mg vial 114.8USD vial Dilaudid Sterile Powder 250 mg/vial 78.99USD vial HYDROmorphone HCl 6 3 mg Suppository Box 54.92USD box Hydromorphone Hp 50 50 mg/ml 13.78USD ml Dilaudid-Xp 50 mg/ml 11.82USD ml Hydromorphone 3 mg suppository 11.11USD suppository Dilaudid-Hp-Plus 20 mg/ml 5.08USD ml Hydromorphone Hp 20 20 mg/ml 4.72USD ml Hydromorph Contin 30 mg Controlled-Release Capsule 4.21USD capsule Hydromorph Contin 24 mg Controlled-Release Capsule 3.52USD capsule Dilaudid-Hp 10 mg/ml 3.14USD ml Hydromorphone Hp 10 mg/ml 2.92USD ml Hydromorph Contin 18 mg Controlled-Release Capsule 2.75USD capsule Hydromorphone 10 mg/ml ampul 2.58USD ml Pms-Hydromorphone 3 mg Suppository 2.42USD suppository Dilaudid 4 mg/ml ampul 2.2USD ml Dilaudid 8 mg tablet 2.19USD tablet HYDROmorphone HCl 4 mg/ml Solution 1ml Cartridge 2.07USD cartridge Hydromorph Contin 12 mg Controlled-Release Capsule 1.91USD capsule Dilaudid 2 mg/ml ampul 1.81USD ml Dilaudid 1 mg/ml ampul 1.64USD ml Hydromorphone hcl 8 mg tablet 1.4USD tablet Dilaudid 4 mg tablet 1.36USD tablet Hydromorphone 8 mg tablet 1.32USD tablet Dilaudid 2 mg/ml 1.28USD ml Hydromorphone 2 mg/ml 1.19USD ml Hydromorph Contin 6 mg Controlled-Release Capsule 1.1USD capsule Hydromorphone-ns 0.4 mg/ml 1.08USD ml Hydromorphone-ns 0.3 mg/ ml 1.05USD ml Hydromorphone 2 mg/ml vial 1.02USD ml Hydromorphone-ns 25 mg/25 ml 1.01USD ml Dilaudid 2 mg tablet 1.0USD tablet Hydromorphone-ns 2.5 mg/25 ml 0.96USD ml HYDROmorphone HCl 4 mg tablet 0.8USD tablet HYDROmorphone HCl 2 mg tablet 0.77USD tablet Hydromorph Contin 3 mg Controlled-Release Capsule 0.73USD capsule Hydromorphone 4 mg tablet 0.72USD tablet Dilaudid 8 mg Tablet 0.55USD tablet Hydromorphone-ns 0.2 mg/ml 0.49USD ml Hydromorphone 2 mg tablet 0.37USD tablet Pms-Hydromorphone 8 mg Tablet 0.37USD tablet Dilaudid 4 mg Tablet 0.35USD tablet Dilaudid-5 1 mg/ml liquid 0.33USD ml Hydromorphone-ns 5.5 mg/55 ml 0.33USD ml Dilaudid 2 mg Tablet 0.23USD tablet Pms-Hydromorphone 4 mg Tablet 0.23USD tablet Dilaudid 1 mg Tablet 0.16USD tablet Pms-Hydromorphone 2 mg Tablet 0.15USD tablet Pms-Hydromorphone 1 mg Tablet 0.1USD tablet Dilaudid 1 mg/ml Liquid 0.09USD ml Pms-Hydromorphone 1 mg/ml Liquid 0.07USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5968551 No 1994-12-24 2011-12-24 US US6589960 No 2000-11-09 2020-11-09 US US9248229 No 2014-03-12 2034-03-12 US US9731082 No 2012-04-23 2032-04-23 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 266.5 °C PhysProp logP 0.9 Not Available - Predicted Properties
Property Value Source Water Solubility 4.39 mg/mL ALOGPS logP 1.69 ALOGPS logP 1.62 ChemAxon logS -1.8 ALOGPS pKa (Strongest Acidic) 10.11 ChemAxon pKa (Strongest Basic) 8.59 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 49.77 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 78.26 m3·mol-1 ChemAxon Polarizability 30.02 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9931 Caco-2 permeable + 0.8647 P-glycoprotein substrate Substrate 0.8174 P-glycoprotein inhibitor I Non-inhibitor 0.8497 P-glycoprotein inhibitor II Non-inhibitor 0.9641 Renal organic cation transporter Inhibitor 0.6374 CYP450 2C9 substrate Non-substrate 0.7925 CYP450 2D6 substrate Substrate 0.8618 CYP450 3A4 substrate Substrate 0.7571 CYP450 1A2 substrate Non-inhibitor 0.6918 CYP450 2C9 inhibitor Non-inhibitor 0.9539 CYP450 2D6 inhibitor Non-inhibitor 0.5197 CYP450 2C19 inhibitor Non-inhibitor 0.8088 CYP450 3A4 inhibitor Non-inhibitor 0.8177 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9413 Ames test Non AMES toxic 0.7214 Carcinogenicity Non-carcinogens 0.9554 Biodegradation Not ready biodegradable 0.9815 Rat acute toxicity 2.9191 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8906 hERG inhibition (predictor II) Non-inhibitor 0.8992
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Mass Spectrum (Electron Ionization) MS splash10-002r-6960000000-9f3d9b17d56e032d76c5 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Morphinans
- Sub Class
- Not Available
- Direct Parent
- Morphinans
- Alternative Parents
- Phenanthrenes and derivatives / Isoquinolones and derivatives / Tetralins / Coumarans / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Ketones show 5 more
- Substituents
- Morphinan / Phenanthrene / Isoquinolone / Tetralin / Coumaran / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- morphinane alkaloid, organic heteropentacyclic compound (CHEBI:5790)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
- Gene Name
- OPRM1
- Uniprot ID
- P35372
- Uniprot Name
- Mu-type opioid receptor
- Molecular Weight
- 44778.855 Da
References
- Quigley C: Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002;(1):CD003447. [PubMed:11869661]
- Inturrisi CE: Clinical pharmacology of opioids for pain. Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13. [PubMed:12479250]
- Sarhill N, Walsh D, Nelson KA: Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001 Mar;9(2):84-96. [PubMed:11305075]
- Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC: Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Eur J Pharmacol. 2008 Nov 12;597(1-3):39-45. doi: 10.1016/j.ejphar.2008.08.025. Epub 2008 Aug 30. [PubMed:18789923]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Partial agonist
- General Function
- Opioid receptor activity
- Specific Function
- G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
- Gene Name
- OPRD1
- Uniprot ID
- P41143
- Uniprot Name
- Delta-type opioid receptor
- Molecular Weight
- 40368.235 Da
References
- Fang X, Larson DL, Portoghese PS: 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands. J Med Chem. 1997 Sep 12;40(19):3064-70. [PubMed:9301669]
- Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. [PubMed:2849950]
- Jiang Q, Sebastian A, Archer S, Bidlack JM: 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists. J Pharmacol Exp Ther. 1994 Mar;268(3):1107-13. [PubMed:7511163]
- Guay DR: Use of oral oxymorphone in the elderly. Consult Pharm. 2007 May;22(5):417-30. [PubMed:17658959]
- Hartvig P, Neil A, Terenius L, Antoni G, Rimland A, Ulin J, Langstrom B: Brain and plasma kinetics of the opioid 11C-hydromorphone in two macaque species. Pharmacol Toxicol. 1989 Sep;65(3):214-6. [PubMed:2478994]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Opioid receptor activity
- Specific Function
- G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
- Gene Name
- OPRK1
- Uniprot ID
- P41145
- Uniprot Name
- Kappa-type opioid receptor
- Molecular Weight
- 42644.665 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J: Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. [PubMed:16433932]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Retinoic acid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
- Gene Name
- UGT1A9
- Uniprot ID
- O60656
- Uniprot Name
- UDP-glucuronosyltransferase 1-9
- Molecular Weight
- 59940.495 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2018 19:23